Cutaneous Adverse Drug Reactions in Hospitalized HIV/AIDS Patients
Downloads
Background: Cutaneous adverse drug reaction (CADR) is the most common manifestation of drug hypersensitivity in human
immunodeficiency virus (HIV), which presented as maculopapular rash. The incidence of CADR is found to be more common
in untreated HIV patients, and the frequency is higher in severe immunodeficiency status. Early diagnosis and appropriate
treatment give better outcomes. Purpose: To evaluate the incidence and management of CADR in HIV and acquired immune
deficiency syndrome (AIDS) patients. Methods: A retrospective descriptive study of HIV/AIDS patients with CADR who
were hospitalized at Intermediate Care and Infectious Disease Centre Dr. Soetomo General Academic Hospital. Result: There
were more CADR cases in 2017, accounted 2.35% of the total Intermediate Care and Infectious Disease Centre RSUD Dr.
Soetomo General Academic Teaching Hospital ward patients. There were more male patients (62.5%), with the most
commonly found at the age of 25-44 years (64.3%), and which mostly (89.3%) originated from Surabaya. The most common
diagnosis was morbiliform eruption (60.7%), main complaint was red spots all over the body (45%), all of which are obscure
erythematous macules. The most common causes were Duviral + Neviral antiretroviral (46%) and the most common treatment
was dexamethasone injection. Conclusion: The incidence of CADR increased in 2017. The most frequent manifestation was
morbilliform eruption due to Duviral+Neviral as the first line ARV treatment. Skin management varies widely in form of
topical, oral, and intravenous injection drugs, mostly using steroid class, dexamethasone intravenous injection in particular.
Altman K, Vanness E, Westergaard RP. Cutaneous manifestations of human immunodeficiency virus: a clinical update. Curr Infect Dis Rep 2015 Mar; 17 (3): 464-76.
Davarpanah M, Motazedian N, Jowkar F. Dermatological manifestations of HIV/AIDS individuals in Shiraz, South of Iran. J Global Infect Dis 2018; 10 (2): 80-3.
Malani PN. Human immunodeficiency virus. JAMA 2016 Jul 12; 316 (2): 238-39.
Maharani PN, Suwarsa O, Prodjosoewojo S. Clinical profile of adverse cutaenous drug reactions in patients with human immunodeficiency virus. AMJ 2020 Dec; 7 (4): 200-5
Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma Clin Immunol 2018 Sep; 14 (S2): 129-39.
Sousa-Pinto B, Correia C, Gomes L, Gil-Mata S, Araújo L, Correia O, et al. HLA and delayed drug-induced hypersensitivity. Int Arch Allergy Immunol 2016; 170 (3): 163–79.
Pavlos R, White KD, Wanjalla C, Mallal SA, Phillips EJ. Severe delayed drug reactions. Immunology and Allergy Clinics of North America 2017 Nov; 37 (4): 785–815.
Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, et al. Comparative safety of antiretroviral treatment regimens in pregnancy. JAMA Pediatr 2017 Oct 2; 171 (10): E1-9.
Karami Z, Mesdaghi M, Karimzadeh P, Mansouri M, Taghdiri MM, Kayhanidoost Z, et al. Evaluation of lymphocyte transformation test results in patients with delayed hypersensitivity reactions following the use of anticonvulsant drugs. Int Arch Allergy Immunol 2016; 170 (3): 158–62.
Khan K, Khan AH, Sulaiman SA, Soo CT, Akhtar A. Adverse drug reactions in HIV/AIDS patients at a tertiary care hospital in Penang, Malaysia. Jpn J Infect Dis 2016; 69 (1): 56–9.
Alexoudi I, Katsarou A, Paparizos V, Oikonomou K, Kourkounti S, Augerinou G, et al. Dermatological conditions associated with HIV medication in a cohort of Greek patients initiating antiretroviral therapy: 1988–2013. Journal of Virus Eradication 2018 Jan; 4 (1): 26–9.
Hidayati A, Budiono S, Triono E. Terapi anti retrovirus (ARV) pada pasien HIV dan AIDS. In: Manifestasi dan tatalaksana kelainan kulit dan kelamin pada pasien HIV/AIDS. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2018. p. 293–313.
Deng Q, Fang X, Zeng Q, Lu J, Jing C, Huang J. Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis. An Bras Dermatol 2017 Jun; 92 (3): 345–9.
Brandariz D, Smithson A, Anton-Vazquez V. Drug reaction with eosinophilia and systemic symptoms related to antiretroviral treatment in human immunodeficiency virus patients. Indian J Sex Transm Dis 2017; 38 (2): 163-70.
Riono P, Challacombe SJ. HIV in Indonesia and in neighbouring countries and its social impact. Oral Dis 2020 Sep; 26 (S1): 28–33.
Thakkar S, Patel T, Vahora R, Bhabhor P, Patel R. Cutaneous adverse drug reactions in a tertiary care teaching hospital in India: An intensive monitoring study. Indian J Dermatol 2017; 62 (6): 510-7.
Manchanda Y, Das S, Sarda A, Biswas P. Controversies in the management of cutaneous adverse drug reactions. Indian J Dermatol 2018 Apr; 63 (2): 125–30.
Birbal S, Dheda M, Ojewole E, Oosthuizen F. Adverse drug reactions associated with antiretroviral therapy in South Africa. Afr J AIDS Res 2016 Sep; 15 (3): 243–8.
Sachdeva RK, Sharma A, De D, Malhi J, Rewari BB, Singh S, et al. Lamivudine-induced skin rash remains an underdiagnosed entity in HIV: a case series from a single center. JIAPAC 2016 Mar; 15 (2): 153–8.
Paik S. Fatal nevirapine-induced toxic epidermal necrolysis in a HIV infected patient. JCDR 2016; 10 (3): FD03-6.
Hoosen K, Mosam A, Dlova NC, Grayson W. An update on adverse cutaneous drug reactions in HIV/AIDS. Dermatopathology 2019 Jun 26; 6 (2): 111–25.
Kementerian Kesehatan Republik Indonesia. Pedoman nasional tatalaksana klinis infeksi HIV dan terapi antiretroviral pada orang dewasa dan remaja. Jakarta: Kementerian Kesehatan Republik Indonesia Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan; 2012.
Damayanti, Hutomo M, Prakoeswa C, Suyoso S. Sindroma Steven Johnson. In: Panduan praktik klinis SMF Ilmu Kesehatan Kulit dan Kelamin RSUD Dr Soetomo. Surabaya: Universitas Airlangga Press; 2014. p. 18–9.
Damayanti, Hutomo M, Prakoeswa C. Erupsi Obat Morbilis. In: Panduan praktik klinis SMF Ilmu Kesehatan Kulit dan Kelamin RSUD Dr Soetomo. Surabaya: Universitas Airlangga Press; 2013. p. 16-7.
Copyright (c) 2021 Berkala Ilmu Kesehatan Kulit dan Kelamin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
